Elevated nuclear YBX1 expression and the clinicopathological characteristics of patients with solid tumors: a meta-analysis

References

• Zhou LL, Ni J, Feng WT, et al. High YBX1 expression indicates poor prognosis and promotes cell migration and invasion in nasopharyngeal carcinoma. Exp Cell Res. 2017;361(1):126–134. doi:10.1016/j.yexcr.2017.10.00929024700
   PubMed Web of Science ®Google Scholar
• Kim ER, Selyutina AA, Buldakov IA, Evdokimova V, Ovchinnikov LP, Sorokin AV. The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA damaging stress. Cell Cycle. 2013;12(24):3791–3803. doi:10.4161/cc.2667024107631
   PubMed Web of Science ®Google Scholar
• Mitte C. Regulation of mRNA expression in drug-sensitive and drug-resistant gastric carcinoma cells is Independent of YB-1 expression. Anticancer Res. 2010;30:693–698. 20332492
   PubMed Web of Science ®Google Scholar
• Mitte C, Kurucz R, Treue D, Lage H. Effect of YB-1 on the regulation of micro RNA expression in drug-sensitive and drug-resistant gastric carcinoma cells. Anticancer Res. 2010;30:629–634. 20332481
   PubMed Web of Science ®Google Scholar
• Sinnberg T, Sauer B, Holm P, et al. MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop. Exp Dermatol. 2012;21(4):265–270. doi:10.1111/j.1600-0625.2012.01448.x22417301
   PubMed Web of Science ®Google Scholar
• Shiota M, Yokomizo A, Tada Y, et al. P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance. Cancer Sci. 2010;101(8):1797–1806. doi:10.1111/j.1349-7006.2010.01598.x20491776
   PubMed Web of Science ®Google Scholar
• Yamashita T, Higashi M, Momose S, Morozumi M, Tamaru JI. Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer. Int J Oncol. 2017;51(2):579–586. doi:10.3892/ijo.2017.403128714514
   PubMed Web of Science ®Google Scholar
• Lovett DH, Cheng S, Cape L, Pollock AS, Mertens PR. YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochem Biophys Res Commun. 2010;398(3):482–488. doi:10.1016/j.bbrc.2010.06.10420599698
   PubMed Web of Science ®Google Scholar
• Oda Y, Ohishi Y, Saito T, et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol. 2003;199(2):251–258. doi:10.1002/path.128212533839
   PubMed Web of Science ®Google Scholar
• Shiraiwa S, Kinugasa T, Kawahara A, et al. Nuclear Y-box-binding protein-1 expression predicts poor clinical outcome in stage III COLORECTAL CANCEr. Anticancer Res. 2016;36(7):3781–3788. 27354655
   PubMed Web of Science ®Google Scholar
• Lee A, Woo J, Park H, et al. The value of cytoplasmic Y-box-binding protein 1 as a prognostic marker for breast cancer in Korean. Breast Cancer. 2016;23(5):685–691. doi:10.1007/s12282-015-0625-826193840
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi:10.1007/s10654-010-9491-z20652370
   PubMed Web of Science ®Google Scholar
• Zhao ZH, Liao Y, Li J, et al. Association between higher expression of YB-1 and poor prognosis in early-stage extranodal nasal-type natural killer/T-cell lymphoma. Biomarkers Med. 2014;8(4):581–588. doi:10.2217/bmm.14.4
   PubMed Web of Science ®Google Scholar
• Abd El-Maqsoud NMR, Osman NAA, Abd El-Hamid AMA, Fath El-Bab TK, Galal EM. Golgi phosphoprotein-3 and Y-box-binding protein-1 are novel markers correlating with poor prognosis in prostate cancer. Clin Genitourin Cancer. 2016;14(2):e143–e152. doi:10.1016/j.clgc.2015.12.01526794392
   PubMed Web of Science ®Google Scholar
• Dahl E, En-Nia A, Wiesmann F, et al. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer. 2009;9:410. doi:10.1186/1471-2407-9-41019930682
   PubMed Web of Science ®Google Scholar
• El-Naggar AM, Veinotte CJ, Cheng H, et al. Translational activation of HIF1alpha by YB-1 promotes sarcoma metastasis. Cancer Cell. 2015;27(5):682–697. doi:10.1016/j.ccell.2015.04.00325965573
   PubMed Web of Science ®Google Scholar
• Gessner C, Woischwill C, Schumacher A, et al. Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer. Eur Respir J. 2004;23(1):14–19. 14738225
   PubMed Web of Science ®Google Scholar
• Gluz O, Mengele K, Schmitt M, et al. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol. 2009;27(36):6144–6151. doi:10.1200/JCO.2008.19.626119901122
   PubMed Web of Science ®Google Scholar
• Habibi G, Leung S, Law JH, et al. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 2008;10(5):R86. doi:10.1186/bcr215618925950
   PubMed Web of Science ®Google Scholar
• Hyogotani A, Ito K, Yoshida K, Izumi H, Kohno K, Amano J. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer. Clin Lung Cancer. 2012;13(5):375–384. doi:10.1016/j.cllc.2011.11.00622284440
   PubMed Web of Science ®Google Scholar
• Imada K, Shiota M, Kohashi K, et al. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression. Clin Cancer Res. 2013;19:4638–4650. doi:10.1158/1078-0432.CCR-12-370523838318
   PubMed Web of Science ®Google Scholar
• Iwanami T, Uramoto H, Nakagawa M, et al. Clinical significance of epithelial-mesenchymal transition-associated markers in malignant pleural mesothelioma. Oncology. 2014;86(2):109–116. doi:10.1159/00035687424457449
   PubMed Web of Science ®Google Scholar
• Jurchott K, Kuban RJ, Krech T, et al. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet. 2010;6(12):e1001231. doi:10.1371/journal.pgen.100123121170361
   PubMed Web of Science ®Google Scholar
• Kashihara M, Azuma K, Kawahara A, et al. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol. 2009;4:1066–1074. doi:10.1097/JTO.0b013e3181ae282819648825
   PubMed Web of Science ®Google Scholar
• Liu Q, Tao T, Liu F, Ni R, Lu C, Shen A. Hyper-O-GlcNAcylation of YB-1 affects Ser102 phosphorylation and promotes cell proliferation in hepatocellular carcinoma. Exp Cell Res. 2016;349(2):230–238. doi:10.1016/j.yexcr.2016.10.01127751836
   PubMed Web of Science ®Google Scholar
• Nishio S, Ushijima K, Yamaguchi T, et al. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer. Gynecol Oncol. 2014;132(3):703–708. doi:10.1016/j.ygyno.2014.01.04524486603
   PubMed Web of Science ®Google Scholar
• Saji H, Toi M, Saji S, Koike M, Kohno K, Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett. 2003;190:191–197. 12565174
   PubMed Web of Science ®Google Scholar
• Shibahara K, Sugio K, Osaki T, et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res. 2001;7:3151–3155. 11595709
   PubMed Web of Science ®Google Scholar
• Shiraiwa S, Kinugasa T, Kawahara A, et al. Nuclear Y-box-binding protein-1 expression predicts poor clinical outcome in stage III colorectal cancer. Anticancer Res. 2016;36:3781–3788. 27354655
   PubMed Web of Science ®Google Scholar
• Song YH, Shiota M, Yokomizo A, et al. Twist1 and Y-box-binding protein-1 are potential prognostic factors in bladder cancer. Urol Oncol. 2014;32(1):31e31–31e37. doi:10.1016/j.urolonc.2012.11.003
   Web of Science ®Google Scholar
• Szczuraszek K, Halon A, Materna V, et al. Elevated YB-1 expression is a new unfavorable prognostic factor in Non-Hodgkin’s lymphomas. Anticancer Res. 2011;31:2963–2970. 21868545
   PubMed Web of Science ®Google Scholar
• Tay WL, Yip GW, Tan PH, et al. Y-box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol. 2009;22(2):282–290. doi:10.1038/modpathol.2008.18118978732
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen Y, Geng H, Qi C, Liu Y, Yue D. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas. Tumour Biol. 2015;36(9):7159–7166. doi:10.1007/s13277-015-3417-z25877750
   PubMedGoogle Scholar
• Wu Y, Yamada S, Izumi H, et al. Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer. J Surg Oncol. 2012;105(7):724–730. doi:10.1002/jso.2303022215526
   PubMed Web of Science ®Google Scholar
• Yan XB, Yan LL, Zhou J, et al. High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer. Int J Clin Exp Pathol. 2014;7(12):8715–8723. 25674237
   PubMed Web of Science ®Google Scholar
• Zhao S, Guo W, Li J, et al. High expression of Y-box-binding protein 1 correlates with poor prognosis and early recurrence in patients with small invasive lung adenocarcinoma. Onco Targets Ther. 2016;9:2683–2692. doi:10.2147/OTT.S9993927217779
   PubMed Web of Science ®Google Scholar
• Maciejczyk A, Szelachowska J, Ekiert M, et al. Elevated nuclear YB1 expression is associated with poor survival of patients with early breast cancer. Anticancer Res. 2012;32(8):3177–3184. 22843890
   PubMed Web of Science ®Google Scholar
• Kang Y, Hu W, Ivan C, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013;105(19):1485–1495. doi:10.1093/jnci/djt21024062525
   PubMedGoogle Scholar